CliffBio
small molecule

DICLOFENAC POTASSIUM

DICLOFENAC POTASSIUM

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameDICLOFENAC POTASSIUM
Active ingredientDICLOFENAC POTASSIUM
Strength50MG
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2024
Marketing statusRX

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.